特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

乾癬性関節炎治療薬の世界市場:成長、動向、および予測

Psoriatic Arthritis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921254
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=106.61円で換算しております。
乾癬性関節炎治療薬の世界市場:成長、動向、および予測 Psoriatic Arthritis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 112 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

乾癬性関節炎は、遺伝的要因と環境的要因の両方が主要な役割を果たすと考えられています。肥満率の増加やアルコールや喫煙に耽る不健康なライフスタイル、新しい治療法の開発などが乾癬性関節炎治療市場の成長を牽引すると考えられています。また、同市場のシェアは非ステロイド性抗炎症薬(NSAID)が大きく占めると予測されています。研究と技術の進歩により、副作用の少ない安全なNSAIDが開発されており、NSAIDの成長を後押しすると期待されています。ただし、乾癬性関節炎治療薬の副作用と薬物承認のための厳しい規制は、同市場の成長を抑制する要因です。

当レポートは世界の乾癬性関節炎治療市場について調査しており、市場機会や動向、成長および抑制要因、薬剤クラス・投与経路・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • 肥満の有病率の増加
    • 不健康なライフスタイル
    • 先進研究による新しい治療学の出現
  • 市場抑制要因
    • 薬物承認のための厳しい規制
    • 治療薬の副作用
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 薬物クラス別
    • 非ステロイド性抗炎症薬(NSAID)
    • 疾患修飾性抗リウマチ薬(DMARD)
    • 免疫抑制剤
    • 生物製剤
    • その他
  • 投与経路別
    • 経口
    • 非経口
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Pfizer
    • エーザイ株式会社
    • UCB Biosciences Inc
    • Sanofi
    • 大塚製薬株式会社
    • 大日本住友製薬株式会社
    • Johnson & Johnson
    • Celgene Corporation
    • AbbVie Inc.

第7章 市場機会および今後の動向

目次
Product Code: 67102

Market Overview

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis, which is a condition that develops red patches on the skin with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis. However, the joint problems can sometimes begin before skin patches appear. This condition develops when the immune system begins to attack healthy cells and tissue. The abnormal immune response causes inflammation in the joints as well as overproduction of skin cells.

Although it is unclear what triggers the self-harm from the immune system, it is likely that both genetic and environmental factors play a major role. One of the major factors that can exacerbate the development of psoriatic arthritis in obesity. According to OECD 2017 data, nearly 37% of the population of the United States was classified as obese and the report projects the population to increase to 47% by 2030. Hence, as the prevalence of obesity increases, the risk of psoriatic arthritis is expected to increase as well. Other factors like unhealthy lifestyle with indulgence in alcohol and smoking can also be attributed as risk factors for the development of psoriatic arthritis. Moreover, the development of new therapeutic methods is also expected to drive the growth of this market.

However, side effects from psoriatic arthritis therapeutic drugs and stringent regulations for drug approval are restraining the growth of this market.

Scope of the Report

Psoriatic Arthritis therapeutics includes drugs that help relieve pain, reduce inflammation, slow the progression of psoriatic arthritis or directly target parts immune system that triggers inflammation. In the report, a detailed analysis of the psoriatic arthritis therapeutics market is provided. The market is segmented by drug class, route of administration and geography.

Key Market Trends

Non-Steroidal Anti-Inflammatory Drugs (NSAID) are expected to hold a large share in Psoriatic Arthritis Therapeutics Market

NSAIDs are considered the first treatment option for psoriatic arthritis. For people diagnosed with psoriatic arthritis that show only mild symptoms of joint pain and swelling, NSAIDs are usually the first treatment option to consider. NSAIDs are also commonly used as an adjunct treatment in conjunction with biologics or disease-modifying antirheumatic drugs (DMAD) and to treat some severe cases. However, NSAIDs are not advised for people with severe psoriasis because it can cause skin flare-ups. However, with advancements in research and technology, safer NSAIDs have been developed with lesser side-effects. This is expected to help the growth of NSAIDs.

North America dominates the market

According to the 2017 center of disease control and prevention data, the prevalence of obesity has shown an increasing trend among adults in the United States. As per the report, the prevalence of obesity was nearly 30% in 2001-2002 among adults in the US. However, this ratio increased to nearly 40% in 2015-2016. According to OECD, Mexico has one of the highest prevalence of Obesity in the world. As obesity is one of the risk factors of psoriatic arthritis, the high and increasing prevalence is also expected to increase the prevalence of psoriatic arthritis in the future.

However, developed countries like the US and Canada have a structured healthcare system that has a fast adoption rate for newer drugs, therapies, and technologies. Hence, expenditure on psoriatic arthritis therapeutics is expected to increase with increasing prevalence in the future.

Competitive Landscape

The majority of the key player involved in research and manufacturing of psoriatic arthritis therapy drugs are established in developed countries. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market growth.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Obesity
    • 4.2.2 Adoption of Unhealthy Lifestyle
    • 4.2.3 Emergence of new Therapeutics with Advanced Research
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for Drug Approval
    • 4.3.2 Side Effects from Therapeutic drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Nonsteroidal anti-inflammatory drugs (NSAIDs)
    • 5.1.2 Disease-modifying Antirheumatic Drugs (DMARDs)
    • 5.1.3 Immunosuppressants
    • 5.1.4 Biologic agents
    • 5.1.5 Others
  • 5.2 By Route of Administration
    • 5.2.1 Oral
    • 5.2.2 Parenteral
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer
    • 6.1.2 Eisai Inc
    • 6.1.3 UCB Biosciences Inc
    • 6.1.4 Sanofi
    • 6.1.5 Otsuka Pharmaceutical
    • 6.1.6 Sumitomo Dainippon Pharma Co
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Celgene Corporation
    • 6.1.9 AbbVie Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS